首页> 外国专利> USE OF TIAZOLIDINODIONA DERIVATIVES AND ANTI-HYPERGICEMIC AGENTS RELATED TO TREATMENT OF PATHOLOGIES AT RISK TO EVOLVE FOR DIABETES MELLITUS NAO-INSULINO-DEPENDENT

USE OF TIAZOLIDINODIONA DERIVATIVES AND ANTI-HYPERGICEMIC AGENTS RELATED TO TREATMENT OF PATHOLOGIES AT RISK TO EVOLVE FOR DIABETES MELLITUS NAO-INSULINO-DEPENDENT

机译:与恶性疾病有关的使用噻唑烷二酮衍生物和抗高血糖剂可能会引起糖尿病的发展

摘要

Treatment of impaired glucose tolerance, in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus comprises admin. of :(a)eg. a cpd. of formulae (I) or (II)(or a salt of these);(b) a cpd. of formula (IV) (or a cationic salt of (IV), or an acid addn. salt of (IV) when it contains a basic N atom);(c) a cpd. of formula (V) (or a cationic salt of (V), or an acid addn. salt of (V) when A or B is N);or (d) eg. a cpd. of formulae (VII) (or a tautomer, salt or solvate): R1, R2 = H or 1-5C alkyl; R3 = H, 1-6C aliphatic acyl,etc.;R4, R5 = H, 1-5C alkyl or 1-5C alkoxy; or R4+R5 = 1-4C alkylenedioxy; m = 1- 3; W = CH2 or CO etc.;Y, Z = O or NH; R11 = opt. substd. alkyl, alkoxy,etc.;L1, L2 = H or lower alkyl; or L1+L2 = alkylene;V = CH=CH, N=CH, CH=N or S; Za = H, 1-7C alkyl, 3-7C cycloalkyl,etc.;Z1 = H or 1-3C alkyl;q = 1- 3; A, B = CH or N, provided that they are not both N; X1 = S, O, SO2,etc.; s = 0-1; Y1 = CHR20 or R21; Z2 = CHR22, CH2CH2, CH=CH,etc.;R1y is not given; X2, X3 = H, Me, CF3, phenyl,etc. A2 = alkyl, opt. substd. aryl or opt. substd. aralkyl; A3 = a benzene ring with ~3 opt. substits.;R24 = H, alkyl, acyl, or opt. substd. aryl or aralkyl; or A2+R24 = 2-3C polymethylene (opt. substd. by alkyl or aryl, adjacent substits. together with the methylene carbon atoms opt. forming an opt. substd. phenylene gp.); R25, R26 = H; or R25+R26 = a bond; X4 = O or S; n = 2-6.
机译:为了预防或延迟非胰岛素依赖性糖尿病的发作,需要治疗葡萄糖耐量减低。的:(a)例如cpd。式(I)或(II)的盐(或其盐);(b)cpd。式(IV)的化合物(或(IV)的阳离子盐,或(IV)包含碱性N原子的酸加成盐);(c)cpd。式(V)的化合物(或(V)的阳离子盐,或当A或B为N时的(V)的酸加成盐);或(d),例如。 cpd。式(VII)的化合物(或互变异构体,盐或溶剂合物):R 1,R 2 = H或1-5C的烷基; R3 = H,1-6C脂肪族酰基等; R4,R5 = H,1-5C烷基或1-5C烷氧基;或R 4 + R 5 = 1-4C亚烷基二氧基;或m = 1-3; W = CH2或CO等; Y,Z = O或NH; R11 =最佳。取代烷基,烷氧基等; L 1,L 2 = H或低级烷基;或L1 + L2 =亚烷基; V = CH = CH,N = CH,CH = N或S;或Za = H,1-7C烷基,3-7C环烷基等; Z1 = H或1-3C烷基; q = 1-3; A,B = CH或N,前提是它们都不都是N; X1 = S,O,SO2等; s = 0-1; Y1 = CHR20或R21; Z2 = CHR22,CH2CH2,CH = CH等;未给出R1y; X2,X3 = H,Me,CF3,苯基等A2 =烷基,可选。取代芳基或选择。取代芳烷基; A3 =约 3的苯环。 R24 = H,烷基,酰基或opt。取代芳基或芳烷基;或A 2 + R 24 = 2-3C聚亚甲基(由烷基或芳基取代,与亚甲基碳原子一起形成取代亚苯基)。 R25,R26 = H;或R25 + R26 =键; X4 = O或S; n = 2-6。

著录项

  • 公开/公告号PT719143E

    专利类型

  • 公开/公告日2001-03-30

    原文格式PDF

  • 申请/专利权人 WARNER-LAMBERT COMPANY;

    申请/专利号PT19940928068T

  • 申请日1994-09-09

  • 分类号A61K31/425;A61K31/44;A61K31/41;

  • 国家 PT

  • 入库时间 2022-08-22 01:23:58

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号